A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
Background Identification of pharmacodynamic interactions is not reasonable to carry out in
a clinical setting for many reasons. The aim of this work was to develop a model-informed …
a clinical setting for many reasons. The aim of this work was to develop a model-informed …
Translational model‐informed approach for selection of tuberculosis drug combination regimens in early clinical development
BO Susanto, SG Wicha, Y Hu… - Clinical …, 2020 - Wiley Online Library
The development of optimal treatment regimens in tuberculosis (TB) remains challenging
due to the need of combination therapy and possibility of pharmacodynamic (PD) …
due to the need of combination therapy and possibility of pharmacodynamic (PD) …
Comparisons of analysis methods for assessment of pharmacodynamic interactions including design recommendations
Quantitative evaluation of potential pharmacodynamic (PD) interactions is important in
tuberculosis drug development in order to optimize Phase 2b drug selection and ultimately …
tuberculosis drug development in order to optimize Phase 2b drug selection and ultimately …
Assessing pharmacodynamic interactions in mice using the multistate tuberculosis pharmacometric and general pharmacodynamic interaction models
The aim of this study was to investigate pharmacodynamic (PD) interactions in mice infected
with Mycobacterium tuberculosis using population pharmacokinetics (PKs), the Multistate …
with Mycobacterium tuberculosis using population pharmacokinetics (PKs), the Multistate …
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB
For rapid anti-tuberculosis (TB) drug development in vitro pharmacokinetic/
pharmacodynamic (PK/PD) models are useful in evaluating the direct interaction between …
pharmacodynamic (PK/PD) models are useful in evaluating the direct interaction between …
Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
RJ Svensson, SH Gillespie… - Journal of Antimicrobial …, 2017 - academic.oup.com
Background: The demand for new anti-TB drugs is high, but development programmes are
long and costly. Consequently there is a need for new strategies capable of accelerating this …
long and costly. Consequently there is a need for new strategies capable of accelerating this …
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis
MA Lyons, A Obregon-Henao, ME Ramey… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
ABSTRACT A major challenge for tuberculosis (TB) drug development is to prioritize
promising combination regimens from a large and growing number of possibilities. This …
promising combination regimens from a large and growing number of possibilities. This …
Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations
RC Van Wijk, R Ayoun Alsoud, H Lennernäs… - Applied Sciences, 2020 - mdpi.com
Featured Application Model-informed drug discovery and development (MID3) is proposed
to be applied throughout the preclinical to clinical phases to provide an informative …
to be applied throughout the preclinical to clinical phases to provide an informative …
The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs
HI Bax, IAJM Bakker-Woudenberg, CP de Vogel… - Tuberculosis, 2017 - Elsevier
Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …
The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis …
C Chen, F Ortega, J Rullas, L Alameda… - … of pharmacokinetics and …, 2017 - Springer
Abstract The Multistate Tuberculosis Pharmacometric (MTP) model, a pharmacokinetic-
pharmacodynamic disease model, has been used to describe the effects of rifampicin on …
pharmacodynamic disease model, has been used to describe the effects of rifampicin on …